Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 5/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18735831 | 1.00 | PDCD1LG2 (0.43) | PDCD1LG2CD274SYKMEN1KMT2A | |
| SCHEMBL18735833 | 1.00 | PDCD1LG2 (0.43) | PDCD1LG2CD274SYKMEN1KMT2A | |
| SCHEMBL20245161 | 0.93 | SYK (0.41) | PDCD1LG2CD274SYKMEN1KMT2A | |
| SCHEMBL20245032 | 0.93 | SYK (0.41) | PDCD1LG2CD274SYKMEN1KMT2A | |
| SCHEMBL20245027 | 0.93 | SYK (0.41) | PDCD1LG2CD274SYKMEN1KMT2A | |
| SCHEMBL18719715 | 0.93 | SYK (0.40) | PDCD1LG2CD274SYKMEN1KMT2A | |
| SCHEMBL20244973 | 0.92 | PDCD1LG2 (0.42) | PDCD1LG2CD274SYKMEN1KMT2A | |
| SCHEMBL20245152 | 0.90 | GRB2 (0.36) | PDCD1LG2CD274SYKMEN1KMT2A | |
| SCHEMBL20244977 | 0.90 | GRB2 (0.36) | PDCD1LG2CD274SYKMEN1KMT2A | |
| SCHEMBL20244991 | 0.90 | GRB2 (0.36) | PDCD1LG2CD274SYKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101444-A1 | Cyclic Peptidomimetic Compounds as Immunomodulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101444-A1 | Cyclic Peptidomimetic Compounds as Immunomodulators | CD274, PDCD1LG2, PDCD1 | PDCD1LG2 2/4885CD274 1/4885SYK 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.